Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 78Neoplasms 69Prostatic Neoplasms 51Colorectal Neoplasms 45Lung Neoplasms 39Carcinoma, Non-Small-Cell Lung 28Hematologic Neoplasms 22Pancreatic Neoplasms 21Neoplasm Metastasis 20Head and Neck Neoplasms 20Urinary Bladder Neoplasms 15Ovarian Neoplasms 15Multiple Myeloma 15Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Motor Activity 11Leukemia, Myeloid, Acute 11Glioblastoma 10Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Gastrointestinal Neoplasms 9Colonic Neoplasms 9Melanoma 8Hematopoietic and Lymphatic System Neoplasm 8Glioma 8Esophageal Neoplasms 8Carcinoma, Renal Cell 8COVID-19 8Anxiety Disorders 8Anatomic Stage I Breast Cancer AJCC v8 8

Interventions

Mitomycin 3vofatamab 2pembrolizumab 2Standard of Care 2Cystectomy 2B701 protein, Human herpesvirus 6 2valrubicin 1trifluridine tipiracil drug combination 1testosterone 17 beta-cypionate 1palbociclib 1enfortumab vedotin 1atezolizumab 1Water 1Valsartan 1Urinary Diversion 1Tranexamic Acid 1Therapeutics 1Testosterone Propionate 1Sunitinib 1Stents 1Radiosurgery 1Radiation Dose Hypofractionation 1Practice Guidelines as Topic 1Nephrotomy 1Nephrostomy, Percutaneous 1Methyltestosterone 1Immune Checkpoint Inhibitors 1Ice 1Hydroxychloroquine 1Health Information Exchange 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urologic Diseases × Standard of Care × Clear all
NCT04731376 2026-05-26

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

Emory University

Phase 1 Active not recruiting
56 enrolled
Genitourinary

Hypogonadism, Urologic Diseases, Urologic Neoplasms

NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡